PSEUDOTYPED REPORTER VIRUS PARTICLES (RVPs)
Accelerating the discovery of vaccines and antiviral therapies against SARS-CoV-2, influenza, dengue, Zika, and other viruses
Reporter Virus Particles: Pseudoviruses for Safe Neutralization Data

- Safe in a BSL-2 environment
- Quantitative (luciferase) or fluorescent (GFP) read-out
- Quality-controlled critical reagents based on 20+ years of virology expertise and experience manufacturing reporter viruses
“SARS-CoV-2 RVPs really helped us a lot since we did not have much previous expertise in SARS. The user meetings were especially helpful.”
Accelerating Clinical Development: RVPs for Vaccines and Antibodies
The Integral Advantage: 20+Years of Virology Experience
Deep expertise in virology is at the core of Integral Molecular’s 20-year history, and we have co-authored over 70 peer-reviewed virology publications in journals including Cell, Science and Nature. With the support of NIAID, scientists at Integral Molecular have been on the forefront of combatting viral epidemics including COVID-19, Zika, Ebola, and Chikungunya. Meet our team.
Trusted by 100+ Laboratories for R&D and Clinical Trials

Publications Establishing RVPs as a Critical Reagent
Frequently Asked Questions
Integral Molecular offers many vaccine development solutions including the production of reporter viruses, epitope mapping on viral targets, protein engineering for vaccine discovery, and antibody discovery against viral targets.
Yes. We can produce large lots of RVPs to accommodate screening 100s or 1000s of samples in sera neutralization assays without bridging studies.